| Literature DB >> 34208802 |
Simone Marconcini1,2, Enrica Giammarinaro1, Saverio Cosola1, Giacomo Oldoini1, Annamaria Genovesi1,2, Ugo Covani1,2.
Abstract
BACKGROUND: Periodontal infection may contribute to poor glycemic control and systemic inflammation in diabetic patients. The aim of the present study is to evaluate the efficacy of non-surgical periodontal treatment in diabetic patients by measuring oxidative stress outcomes.Entities:
Keywords: diabetes; lactoferrin; oxidative stress; ozone; periodontal health; reactive oxygen metabolites
Year: 2021 PMID: 34208802 PMCID: PMC8300765 DOI: 10.3390/antiox10071056
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Subject recruitment and treatment allocation flow chart.
Demographic characteristics of the included patients.
| Variable | Mean ± SD |
|---|---|
| No. of patients | 60 |
| No. of DM-1 | 21 |
| No. of DM-2 | 39 |
| No. of males/females | 38/22 |
| No. of smokers | 11 |
| Mean age | 60.9 ± 14.8 years |
| Mean body mass index | 27.8 ± 0.90 |
Mean values (±standard deviations) of clinical periodontal measures at baseline and at one, three, and six months.
| Variables | Time Points | Overall | Treatment Groups | ||
|---|---|---|---|---|---|
|
|
|
| |||
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
|
|
| 3.13 ± 0.36 | 3.13 ± 0.35 | 3.16 ± 0.33 | 3.09 ± 0.39 |
|
| 2.09 ± 0.19 | 2.09 ± 0.12 | 2.07 ± 0.22 | 2.11 ± 0.21 | |
|
| 2.03 ± 0.21 | 2.35 ± 0.39 | 2.02 ± 0.18 | 1.98 ± 0.22 | |
|
| 2.10 ± 0.21 | 2.11 ± 0.19 | 2.09 ± 0.21 | 2.08 ± 0.19 | |
|
|
| 0.85 ± 0.19 | 0.83 ± 0.17 | 0.81 ± 0.21 | 0.89 ± 0.26 |
|
| 0.15 ± 0.05 | 0.13 ± 0.09 | 0.15 ± 0.06 | 0.17 ± 0.05 | |
|
| 0.35 ± 0.14 | 0.33 ± 0.12 | 0.34 ± 0.18 | 0.37 ± 0.09 | |
|
| 0.63 ± 0.07 | 0.65 ± 0.15 | 0.53 ± 0.13 | 0.64 ± 0.18 | |
|
|
| 0.96 ± 0.11 | 0.81 ± 0.18 | 0.94 ± 0.11 | 0.99 ± 0.10 |
|
| 0.41 ± 0.12 | 0.29 ± 0.18 | 0.35 ± 0.10 | 0.45 ± 0.14 | |
|
| 0.31 ± 0.16 | 0.58 ± 0.15 |
|
| |
|
| 0.64 ± 0.13 | 0.69 ± 0.19 | 0.56 ± 0.17 | 0.46 ± 0.18 |
* The mean values in bold are significantly different from the chlorhexidine group at p < 0.05.
Figure 2The BoP values decreased for all groups evaluated et each time point, with significant reductions after 1 and 3 months (T1 and T2), values are reported in Table 2.
The outcome measures for reactive oxygen metabolites (dROMs, PAT, SAT) and glycated hemoglobin (HbA1c) were measured at baseline and at one, three, and six months.
| Variable | Time Point | Overall | Treatment Group | ||
|---|---|---|---|---|---|
|
|
|
| |||
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
|
|
| 388 ± 21.36 | 373 ± 27.15 | 399 ± 30.23 | 385 ± 24.34 |
|
| 323 ± 29.19 | 320 ± 23.24 | 328 ± 31.12 | 327 ± 27.26 | |
|
| 294 ± 34.21 | 329 ± 18.29 | 288 ± 40.18 | 291 ± 28.56 | |
|
| 332 ± 31.76 | 336 ± 41.29 | 331 ± 24.19 | 332 ± 34.85 | |
|
|
| 1883 ± 165 | 1880 ± 98.5 | 1847 ± 21.7 | 1819 ± 54.4 |
|
| 1961 ± 131 | 1991 ± 85.9 | 1964 ± 79.7 | 1922 ± 45.4 | |
|
| 2002 ± 152 | 1977 ± 185 | 2346 ± 73.9 | 2264 ± 81.3 | |
|
| 2076 ± 143 | 1907 ± 27.5 | 2258 ± 89.6 | 2060 ± 77.7 | |
|
|
| 2383 ± 360 | 2157 ± 241 | 2347 ± 636 | 2459 ± 874 |
|
| 1751 ± 215 | 1573 ± 343 | 1827 ± 696 | 1969 ± 179 | |
|
| 1687 ± 396 | 1927 ± 402 |
|
| |
|
| 1971 ± 715 | 2173 ± 697 | 1827 ± 596 | 1969 ± 179 | |
|
|
| 7.18 ± 0.92 | 7.10 ± 0.81 | 7.27 ± 0.72 | 7.22 ± 1.03 |
|
| 6.63 ± 0.52 | 6.71 ± 0.55 | 6.58 ± 0.69 | 6.60 ± 0.80 | |
|
| 6.94 ± 0.33 | 7.01 ± 0.29 | 6.86 ± 0.19 | 6.96 ± 0.23 |
* The mean values in bold are significantly different from the chlorhexidine group at p < 0.05.